Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of GSK1203486A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma

NCT00706238 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00706238
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00706238 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of GSK1203486A Antigen-Specific Cancer Immunotherapeutic in Patients With Unresectable and Progressive Metastatic Cutaneous Melanoma
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Terminated
Start date
September 29, 2008
Completion date
January 19, 2011
Enrollment
5 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma